Drugs / Plamotamab
Plamotamab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07230353 | Oct 2025 → Jun 2028 expected | rheumatoid arthritis | Xencor, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT02924402 | Oct 2016 → Apr 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Xencor, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05328102 | Apr 2022 → Feb 2023 | diffuse large B-cell lymphoma | Xencor, Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plamotamab | “Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies” NCT02924402 ↗ |
| Known as | XENP13676 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298130 ↗ |
| Known as | XmAb13676 | “The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously...” NCT07230353 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4298130 ↗ |
| Route | Intravenous | “intravenous (IV) and subcutaneous (SC) administration of XmAb13676” NCT02924402 ↗ |
| Route | Subcutaneous | “intravenous (IV) and subcutaneous (SC) administration of XmAb13676” NCT02924402 ↗ |